Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

27 Sep 2023

Novel Aerosol Apparatus for Inhaler Testing in OINDPs


This case study reviews the development of a novel aerosol collection apparatus, UniDose, for dissolution testing of orally inhaled drug products (OIDPs). The study highlights the limitations of current aerosol collection systems and presents UniDose as a robust method for collection and discriminating the dissolution properties of the aerosolized dose of inhalable formulations. The case study also discusses the potential applications of UniDose, including its use in quality control for evaluating material properties, processing effects on the active ingredient dissolution, and its potential to provide an in vitro-in vivo correlation (IVIVC) based technique for OIDPs. This case study is a valuable resource for anyone interested in the development of OIDPs and the future of inhaler technology.

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »